We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
New Tymbal Resources Ltd | TSXV:NTB | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.02 | 0.01 | 0.02 | 0 | 01:00:00 |
Neptune's Omega-3 nutraceutical, Neptune Krill Oil (NKO) has shown efficacy in human trials in three key areas:
1) Triglyceride and good-and-bad-cholesterol management (hyperlipidemia)
2) Inflammation/Arthritis
3) Adult ADHD. A 120-patient human trial showed that NKO reduced LDL (bad cholesterol) by 33.9%, reduced triglycerides by 11.5%, and increased HDL (good cholesterol) by 43.3%. Anyone who knows the cholesterol/hyperlipidemia space knows that finding a single substance that has these effects (with NO toxicity) is like finding the Holy Grail -- and NKO has no toxicity (it has GRAS status from the FDA).
Recently named a finalist for the 2011 Nutraceutical & Business Technology (NBT) Awards in the category of Outstanding Application in Health Management, Neptune has a wide variety of patented substances and processes in 3 different markets: dietary supplements (nutraceuticals); food/beverage ingredients; and pharmaceuticals.
In addition, Neptune Krill Oil, which appears to be the best source of Omega-3s available today, has multiple blockbuster applications in drug development, yet it avoids the classic pitfall of a cash-burning biotech (running out of money) because Neptune is already generating cash flow and earnings from the sale of their nutraceutical Omega-3 product, Neptune Krill Oil (NKO), while the subsidiary developing the cardiovascular drugs, Acasti Pharma, is scheduled to start generating revenues from the sales of its Medical Food and OTC products in the very near term.
A recent report on the company, their human trials with Krill Oil as well as the cash flow and earnings generating core that gives the stock more substance than most biotechs is now available at:
http://biomedreports.com/2011041365978/neptune-technologies-and-bioresources-presents-significant-value-and-opportunity.html
Investors interested in accessing BioMedReports' complete database of clinical trials and upcoming FDA decisions can go to:
http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html
News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports
About BioMedReports.Com
BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets.
Full disclosures and information about the stocks are available at BioMedReports.Com
Add to Digg Bookmark with del.icio.us Add to Newsvine
Media Contacts Only: Mary Davila Assistant Editor BioMedReports.Com e-mail: Email Contact Tel: +1 323 472 4480 Fax: +1 888 210 3556
1 Year New Tymbal Resources Chart |
1 Month New Tymbal Resources Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions